Glenmark Gets USFDA Nod for Generic Blood Pressure Medicine
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil tablets, used in the treatment of high blood pressure.
The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company said in a statement.
These are generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc.
Glenmark’s Olmesartan Medoxomil tablets will be manufactured by the company’s manufacturing facility located in Goa, it added.
Citing IMS Health sales data for the 12-month period ended March 2017, the company said Benicar achieved annual sales of about $950 million.
Glenmark’s current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA’s (Abbreviated New Drug Application) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 2.17 per cent up at Rs. 625.20 on BSE
You May Interested In
2026-08-06
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Treat Acidity: Use medicines with this Pepto Bismol Active Ingredient
-
The battle for Medicine King! With the onslaught of K drug and the setback of Xiomele, the biggest variable in the world's TOP10 drug rankings in 2022 is who?
-
Facing Omicron, Where is the Next 'Special Medicine'?
-
What Are the Medicine that Requires Refrigeration? All You Need Know
-
China to focus on building quality and efficient TCM service system in next five years
-
Overwhelming influx of alliance procurement: orthopaedics and IOLs
-
Analysis of domestic veterinary drug raw materials market in the 42nd week of 2021 Part 2
-
How far is Chinese patent medicine from the ground?
-
Chinese medicine enters the era of plant extraction
-
Analysis of Import and Export of Chinese Medicines in 2019
Recommend Reading
-
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
Premium Global Chemical Sourcing Requests (27-29July, 2026)
-
This Week, the Overall DMF Market in China Remains Largely Stable with Slight Weakness (9.5-9.12)
-
This Week's Isopropanol Market Prices Slightly Increased (9.8-9.12) in China
-
This Week, China's Titanium Dioxide Market Remains Stable (9.8-9.12)
-
In July, the Chinese anhydrous hydrogen fluoride market showed an upward trend